'Cystic Fibrosis drug trials show promising results'
28 March 2008 17:27:36
Trials of an oral drug to treat cystic fibrosis (CF) have shown promising results so far, the Cystic Fibrosis Foundation has announced.
Life insurance policies may be affected by the research which found patients who took the drug for two weeks saw significant improvements in areas affected by the disease, including lung function.
Scientists working on the second phase of ongoing clinical trials for VX-770, an oral drug which targets a basic defect in CF, reported good results and could affect other studies of treatments for the illness.
Dr Robert Beall, president and chief executive of the foundation said: "The emerging data for VX-770 represents the most exciting results we've seen from a Phase Two trial and increase our confidence that we're on the right track."
CF, a life-threatening disease that affects around 70,000 worldwide, is caused by a genetic mutation that results in a malfunctioning protein which causes an imbalance of salt and water, Medical News Today reports.
This imbalance results in a build-up of mucus in the lungs and other organs, increasing the risk of infection.
At Direct Life we aim to ensure that all of our clients get the best deal possible when purchasing their life insurance, term life assurance, mortgage protection and critical illness life insurance policies online.